Mar 04 2021, 10:41 PM March 03 2021, 5:13 PM March 04 2021, 10:41 PM (Bloomberg) -- An Indian coronavirus vaccine that generated controversy when it was granted emergency approval before finishing its final stage testing has shown to provide strong protection against Covid-19 in an interim analysis of an advanced clinical trial. (Bloomberg) -- An Indian coronavirus vaccine that generated controversy when it was granted emergency approval before finishing its final stage testing has shown to provide strong protection against Covid-19 in an interim analysis of an advanced clinical trial. Covaxin, which was co-developed by Hyderabad-based Bharat Biotech International Ltd. and the Indian Council of Medical Research, showed an efficacy rate of 81% in those without prior infection after a second dose, the company said in a statement Wednesday. Thatâs better than Bharat Biotechâs guidance last year of around 60% and the countryâs benchmark of 50% for vaccines targeting the novel coronavirus.